Global Biochip Markets: Microarrays and Lab-on-a-Chip

  • October 2013
  • -
  • BCC Research
  • -
  • 402 pages

STUDY GOALS AND OBJECTIVES

BCC Research’s goal for this study was to determine the status of current and emerging biochip technologies and products and assess their worldwide growth potential over a five-year period from 2013 to 2018. We were particularly interested in characterizing the biochip markets by type (DNA microarray, protein microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user (R&D tools, drug discovery, and development, diagnostics, sequencing, applied).

A particular focus of this study is the market for biochip-based diagnostics products, which highlights a major future market segment for biochips.

Our key objective was to present a comprehensive discussion of the main commercial biochip technologies and the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

BCC Research previously examined the biochips industry in 2011. Since 2011, numerous industry alliances and acquisitions have occurred, which changes the competitive dynamics. In addition, emerging markets for biochips in diagnostics are beginning to gain traction. These changing industry and market dynamics necessitate a re-examination of the total industry.

The main biochips platforms are also undergoing a transition. DNA microarrays are being influenced by next-generation sequencing applications, as well as exciting new applications in rapid DNA analysis and diagnostics. Protein microarrays continue to make progress in the market, as well as emerging microarray classes (tissue/cell and glycomics).

Lab-on-a-chip (LOAC) applications are becoming more important in point of care diagnostics applications, as well as in drug discovery and development.
Next-generation sequencing (NGS) applications continue to increase as a result of lowered costs and better informatics support.

It is important to keep up with these trends and their influence on the biochips market. This report is intended to guide companies in these industries about the important trends in biochips as well as provide detailed information about the individual market segments and industry dynamics.

CONTRIBUTION OF THE STUDY AND FOR WHOM

BCC Research has compiled a study of the main biochip products that are used in the five end-user segments: research tools, drug discovery and development, diagnostics, sequencing and applied markets. The report discusses the biochip platforms, market growth driving forces, product types, key market applications, companies and alliances, industry dynamics, patents, future market potential and product sales forecasts for 2013 through 2018.

This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life-sciences tools, biodefense, medical devices, polymers, glass, materials, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays and lab-on-a-chip devices, sequencing instruments; antibodies, restriction enzymes or primers; bioinformatics developers; and cancer researchers and clinicians.

SCOPE AND FORMAT

The study scope includes the major biochip platforms, including DNA and protein microarrays, tissue/cell and glycomics microarrays, LOAC products and next-generation sequencing. Each platform is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2013 through 2018. Technology status and market driving forces are discussed. Factors that influence the market are discussed, including growth driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.

In addition to the main LOAC, microarray and sequencing industries, BCC Research profiles several specialized biochip industry segments including the following: DNA analyzers, ion channel screening, digital PCR, label-free detection, nanoarray, peptide microarray, antibody microarray, antibody reagents, multiplex protein diagnostics, circulating tumor cell, prenatal screening, point of care CD4 counting and China’s biochips industries.

Applications for biochips-based diagnostics are highlighted in this report, particularly cancer diagnostics.
New data about biochip substrate types is presented in the report.
BCC Research analyzes patent data for each biochip type.
The industry has grown significantly since the last report, and nearly 300 companies are profiled in this report.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research examines each of the key end-user market segments that will be commercially important during the next five years: research tools, drug discovery and development, diagnostics, next-generation DNA sequencing and applied markets (biodefense, food safety, ag-bio).

Based on this analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2013 through 2018.

Based on research, detailed market size information is provided for 2012, 2013 and 2018. For DNA microarrays, the market is given by end-use industry, substrate material and analysis type. For protein and emerging microarrays, the market is given by end-use industry, substrate type and array type. For LOAC, the market is given by end-use industry and substrate type, as well as by genomic and proteomic use. For next-generation sequencing, the market is given by end-use industry, substrate material and analysis complexity.

The diagnostics market is given by biochip type and by indication. The cancer diagnostics market is given by biochip type and cancer indication.

The geographical market sizes for total biochips, LOAC, microarrays and next-generation sequencing are given for North America, Europe, China, Japan and the rest of the world.

INFORMATION SOURCES

BCC Research used primary sources in industry, government and academia, as well as secondary sources for this study.

ANALYST’S CREDENTIALS

The author, John Bergin, has written numerous previous BCC Research biotechnology reports, including the following: BIO126A Next Generation Sequencing: Emerging Clinical Applications and Global Markets; BIO059BEpigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; BIO049D Global Biochip Markets: Microarrays and Lab-on-a-chip; BIO062A RNA Interference in the Post-Genomics Era: Markets and Technologies; BIO045D DNA Sequencing: Emerging Technologies and Applications; BIO064B Biologic Imaging Reagents: Technologies and Markets; and BIO066B Synthetic Biology: Emerging Global Markets. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: BS Chemistry, MS Biotechnology and Masters of Business Administration.

REPORT HIGHLIGHTS

This report provides:
• An overview of the global market for current and emerging biochip technologies and products
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Characterizations of biochip markets by type (DNA microarray, protein microarray, emerging microarray, and lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end-user (research-and-development tools, drug discovery and development, diagnostics, sequencing, and applied)
• A focused study on the market for biochip-based diagnostics products, a major future segment for biochips
• Discussion of the main commercial biochip technologies and the commercial potential of the key market segments
• Examination of the factors that influence the market, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, and customer needs
• Patent analysis
• Comprehensive company profiles of major players.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
CONTRIBUTION OF THE STUDY AND FOR WHOM 2
SCOPE AND FORMAT 3
METHODOLOGY 3
INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 4
RELATED BCC REPORTS 4
BCC RESEARCH ONLINE SERVICES 5
DISCLAIMER 5

CHAPTER 2 SUMMARY 7

SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH
2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2012-2018
($ MILLIONS) 7

CHAPTER 3 OVERVIEW 10

INTRODUCTION 10
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 11
BIOCHIP TYPES 11
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 12
TABLE 3 BIOCHIP NOMENCLATURE 13
SCOPE OF REPORT 14
TABLE 4 SCOPE OF REPORT 14
MARKET POTENTIAL OF BIOCHIPS 14
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2018
($ MILLIONS) 15
TABLE 6 GLOBAL VALUE OF BIOCHIPS BY ANALYSIS FUNCTION, THROUGH 2018 ($
MILLIONS) 16
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 17
TABLE 7 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES 17
THE BIOCHIP INDUSTRY 18
TABLE 8 COMPARISON OF BIOCHIPS INDUSTRIES 18

CHAPTER 4 MICROARRAY TECHNOLOGIES 21

INTRODUCTION 21
TABLE 9 THE NANOSCALE WORLD 21
TABLE 10 MICROARRAY TYPES 22
TABLE 11 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 22
DNA MICROARRAY TECHNOLOGIES 24
DNA MICROARRAY TYPES 24
FIGURE 1 MICROARRAY FEATURE DENSITY 24
FIGURE 2 MICROARRAY RESOLUTION 24
TABLE 12 MICROARRAY GENOME CONTENT 25
TABLE 13 DNA MICROARRAY PLATFORM FEATURES 26
DNA MICROARRAY APPLICATIONS 27
TABLE 14 DNA MICROARRAY APPLICATIONS 27
TABLE 15 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 28
FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1 29
SNP ANALYSIS 30
TABLE 16 SNP MEASUREMENT PLATFORMS 31
EPIGENETIC ANALYSIS 31
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS 32
CYTOGENETIC ANALYSIS 33
TABLE 17 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 34
MICRO-RNA ANALYSIS 35
TABLE 18 WORKFLOW FOR A MICRO-RNA EXPERIMENT 36
BEAD-BASED ARRAYS 37
TABLE 19 BEAD-BASED ARRAYS VERSUS PLANAR MICROARRAYS 37
CATALOG AND CUSTOM DNA MICROARRAYS 37
PROTEIN MICROARRAY TECHNOLOGIES 37
INTRODUCTION 37
FIGURE 5 IMPORTANCE OF PROTEINS 38
PROTEOMICS WORKFLOW 38
FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED 39
PROTEIN MICROARRAY DESIGN FEATURES 40
TABLE 20 PROTEIN MICROARRAY PLATFORMS 40
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS 41
TABLE 21 PROTEIN MICROARRAYS AS RESEARCH TOOLS 41
PROTEIN MICROARRAY TYPES 42
TABLE 22 PROTEIN MICROARRAY PRODUCT TYPES 42
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 44
TABLE 23 PROTEIN MICROARRAY TECHNICAL CHALLENGES 44
EMERGING MICROARRAY TECHNOLOGIES 47
TABLE 24 EMERGING MICROARRAY TECHNOLOGIES 47
GLYCOMICS MICROARRAYS 47
TISSUE MICROARRAYS 48

CHAPTER 5 LAB-ON-A-CHIP TECHNOLOGIES 51

INTRODUCTION 51
TABLE 25 LOAC PRODUCT LIFE CYCLE STAGE 51
SUBSTRATE MATERIALS 52
TABLE 26 BIOCHIPS SUBSTRATE MATERIALS 52
LOAC TYPES 53
TABLE 27 LOAC TYPES 53
IN VITRO PROTEOMICS 54
ELECTROPHORESIS ON A CHIP 54
STRUCTURAL PROTEOMICS 54
PCR ON A CHIP 55
IMMUNOASSAY ON A CHIP 56
MASS SPECTROMETRY ON CHIP 57
NEXT-GENERATION SEQUENCING ON CHIP 57
TABLE 28 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA
SEQUENCING PLATFORMS 58
TABLE 29 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES 58
LOAC APPLICATIONS 60
TABLE 30 LOAC MARKET SEGMENTS 60
TABLE 31 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 61
ORGAN ON CHIP 61
LOAC TECHNOLOGY CHALLENGES 62
TABLE 32 LOAC TECHNOLOGY CHALLENGES 62

CHAPTER 6 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS 65

INTRODUCTION 65
TABLE 33 BIOCHIP KEY LIFE-SCIENCES MARKET SEGMENTS 65
DRUG INDUSTRY CHALLENGES 66
DRUG DISCOVERY AND DEVELOPMENT PROCESS 67
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 67
TABLE 34 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 68
DRUG TARGET IDENTIFICATION 69
DRUG DISCOVERY 70
Structural Biology 70
Lead Generation 70
Lead Optimization 73
Process RandD 73
Preclinical and Clinical Trials 74
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 74
TABLE 35 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 74
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS 76

CHAPTER 7 DIAGNOSTICS APPLICATIONS 79

INTRODUCTION 79
TABLE 36 DIAGNOSTICS PARADIGM SHIFT 79
HOW DIAGNOSTICS DIFFER FROM RESEARCH TOOLS 80
TABLE 37 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 80
HOW BIOLOGICAL CONTENT DRIVES THE GROWTH OF DIAGNOSTICS 81
TABLE 38 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS 81
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS 83
TABLE 39 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 83
MOLECULAR DIAGNOSTICS 84
INTRODUCTION 84
MARKET CHALLENGES FOR DNA-BASED MDX PLATFORMS 85
TABLE 40 COMPARISON OF DNA-BASED MDX PLATFORMS 86
TABLE 41 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS
INTO THE MDX MARKET 87
DIAGNOSTICS MARKET SEGMENTS 88
TEST SENSITIVITY AND SPECIFICITY 89
FIGURE 9 SENSITIVITY AND SPECIFICITY 90
REGULATORY STATUS 91
BIOCHIPS CANCER APPLICATIONS 91
CANCER OVERVIEW 91
TABLE 42 ESTIMATED U.S. INCIDENCE FOR SELECTED CANCERS, 2012 92
BLADDER CANCER 93
TABLE 43 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 93
BREAST CANCER 95
Breast Cancer Screening 95
Prognosis and Pharmacogenetics Tests 95
TABLE 44 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT
DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 96
Breast Cancer MDx Platforms 97
TABLE 45 BREAST CANCER MDX TECHNOLOGY PLATFORMS 97
TABLE 46 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 98
CERVICAL CANCER 102
TABLE 47 STATUS OF ADVANCED HPV DIAGNOSTICS 104
COLORECTAL CANCER 106
Conventional Colorectal Cancer Screening Tests 107
TABLE 48 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL
CANCER 107
Molecular Colorectal Cancer Diagnostics Tests 108
TABLE 49 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS 108
CANCER OF UNKNOWN PRIMARY (CUP) 110
TABLE 50 CANCER UNKNOWN PRIMARY INDUSTRY 111
KIDNEY CANCER 113
TABLE 51 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 113
LEUKEMIA 114
TABLE 52 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 114
LIVER CANCER 116
TABLE 53 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS 117
LYMPHOMA 118
TABLE 54 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS 118
LUNG CANCER 119
TABLE 55 FIVE-YEAR SURVIVAL RATES FOR NON SMALL CELL LUNG CANCER (%) 119
TABLE 56 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 120
MELANOMA 124
TABLE 57 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 125
OVARIAN CANCER 126
TABLE 58 EARLY SCREENING OVARIAN CANCER TESTS 126
TABLE 59 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS 127
PANCREATIC CANCER 129
TABLE 60 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS 129
PROSTATE CANCER 130
TABLE 61 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 132
THYROID CANCER 135
TABLE 62 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS 135
SUMMARY OF ADVANCED CANCER DIAGNOSTICS 136
TABLE 63 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND BY
TECHNOLOGY 136
WARFARIN SENSITIVITY 137
TABLE 64 IMPORTANCE OF CYP GENES IN DRUG METABOLISM 138
TABLE 65 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC
DIAGNOSTICS 139
INFECTIOUS DISEASES 141
TUBERCULOSIS 141
HOSPITAL-ACQUIRED INFECTIONS 142
TABLE 66 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS 142
INFLUENZA 143
TABLE 67 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 144
SEXUALLY TRANSMITTED DISEASES 145
TABLE 68 STATUS OF CT/NG ADVANCED DIAGNOSTICS 146
OTHER INFECTIOUS DISEASES 146
NEUROLOGICAL 147
ALZHEIMER'S DISEASE 147
TABLE 69 ALZHEIMER’S DISEASE DIAGNOSTICS APPROACHES 148
TABLE 70 STATUS OF ALZHEIMER’S DISEASE ADVANCED DIAGNOSTICS TESTS 148
SCHIZOPHRENIA 149
CARDIAC DISORDERS 150
CONGESTIVE HEART FAILURE 150
TABLE 71 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE 151
CYSTIC FIBROSIS 152
TABLE 72 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS 153
NONINVASIVE PRENATAL SCREENING 154
TABLE 73 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 155
IMMUNE DISORDERS 156
HLA TYPING 156
TABLE 74 HLA TESTING MARKET 157
AUTOIMMUNE TESTING 158

CHAPTER 8 BIOCHIPS INDUSTRY 161

BIOCHIPS INDUSTRY ACQUISITIONS, 2012-2013 161
TABLE 75 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2013 161
BIOCHIPS INDUSTRY STRATEGIC ALLIANCES, 2012-2013 164
MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013 164
TABLE 76 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013 165
LOAC INDUSTRY STRATEGIC ALLIANCES, 2012-2013 169
TABLE 77 LOC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013 169
LOAC INDUSTRY 177
LOAC INDUSTRY OVERVIEW 178
TABLE 78 LOAC COMPETITOR LANDSCAPE 178
LOAC INSTRUMENT INDUSTRY 179
TABLE 79 LEADING LOAC INSTRUMENT MANUFACTURERS 180
LOAC DNA ANALYZER INDUSTRY 181
TABLE 80 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS 181
LOAC DIAGNOSTICS INDUSTRY 182
TABLE 81 LOAC DIAGNOSTICS INDUSTRY 182
ION CHANNEL SCREENING INDUSTRY 182
TABLE 82 ION CHANNEL SCREENING INDUSTRY 183
DIGITAL PCR INDUSTRY 183
TABLE 83 DIGITAL PCR INDUSTRY 184
INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY 185
TABLE 84 LOC UNIVERSITY SPIN-OFFS 185
ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY 186
TABLE 85 LEADING LIFE SCIENCE COMPANIES ACQUISITIONS IN LOAC 186
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY 187
TABLE 86 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES:
COMMERCIAL PHASE 187
MICROARRAY INDUSTRY 188
SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 188
TABLE 87 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 188
LABEL-FREE DETECTION INDUSTRY 189
TABLE 88 LABEL-FREE DETECTION INDUSTRY 189
NANOARRAY INDUSTRY 191
TABLE 89 NANOARRAY INDUSTRY 191
PEPTIDE MICROARRAY INDUSTRY 191
TABLE 90 KEY PEPTIDE MICROARRAY COMPANIES 192
ANTIBODY MICROARRAY INDUSTRY 192
TABLE 91 KEY ANTIBODY MICROARRAY COMPANIES 193
ANTIBODY REAGENTS INDUSTRY 194
TABLE 92 MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES 194
BIOCHIPS DIAGNOSTICS INDUSTRY 195
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY 195
TABLE 93 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES 195
CIRCULATING TUMOR CELL INDUSTRY 197
TABLE 94 CTC BIOCHIPS INDUSTRY 198
PRENATAL DIAGNOSTICS INDUSTRY 199
TABLE 95 NORTH AMERICAN TEST COSTS AND PRICES ($) 200
TABLE 96 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 201
TABLE 97 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE
COMPETITORS 202
POC CD4 COUNTING INDUSTRY 202
TABLE 98 POC CD4 INDUSTRY 203
AGRICULTURAL INDUSTRY 203
TABLE 99 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY 204
CHINA'S BIOCHIP INDUSTRY 205
TABLE 100 CHINA BIOCHIP INDUSTRY 206

CHAPTER 9 BIOCHIPS MARKETS 210

DRIVING FORCES FOR BIOCHIPS GROWTH 210
TABLE 101 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES 210
GLOBAL BIOCHIPS MARKET 211
TABLE 102 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2018 ($
MILLIONS) 211
TABLE 103 GLOBAL VALUE OF BIOCHIP MARKET BY END-USE INDUSTRY, THROUGH
2018 ($ MILLIONS) 212
TABLE 104 BIOCHIPS SUBSTRATE MATERIALS 213
TABLE 105 GLOBAL VALUE OF BIOCHIP MARKET BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 213
DNA MICROARRAY MARKETS 214
DNA MICROARRAY MARKET BY END-USE INDUSTRY 214
TABLE 106 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2018 ($
MILLIONS) 214
DNA MICROARRAY MARKET BY ANALYSIS TYPE 216
TABLE 107 GLOBAL VALUE OF DNA MICROARRAYS BY ANALYSIS TYPE, THROUGH
2018 ($ MILLIONS) 216
FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2013 (NO. OF MIRNAS) 218
DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL 219
TABLE 108 GLOBAL VALUE OF DNA MICROARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 219
PROTEIN MICROARRAYS MARKETS 219
INTRODUCTION 219
TABLE 109 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY 220
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY 221
TABLE 110 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH
2018 ($ MILLIONS) 221
PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL 222
TABLE 111 GLOBAL VALUE OF PROTEOMIC MICROARRAYS BY SUBSTRATE
MATERIAL, THROUGH 2018 ($ MILLIONS) 223
TABLE 112 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 223
PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE 224
TABLE 113 GLOBAL VALUE OF PROTEOMIC ARRAYS BY ARRAY TYPE, THROUGH
2018 ($ MILLIONS) 224
EMERGING MICROARRAYS MARKETS 225
EMERGING MICROARRAYS MARKET BY TECHNOLOGY 225
TABLE 114 GLOBAL VALUE OF EMERGING ARRAYS, BY ARRAY TYPE, THROUGH
2018 ($ MILLIONS) 225
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY 226
TABLE 115 GLOBAL VALUE OF EMERGING ARRAYS BY END USE, THROUGH 2018 ($
MILLIONS) 226
EMERGING ARRAYS MARKET BY SUBSTRATE TYPE 227
TABLE 116 GLOBAL VALUE OF EMERGING ARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 227
LOAC MARKETS 227
GENOMICS LOAC MARKET BY END-USE INDUSTRY 227
TABLE 117 GLOBAL VALUE OF GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY,
THROUGH 2018 ($ MILLIONS) 228
GENOMICS LOAC MARKET BY SUBSTRATE TYPE 229
TABLE 118 GLOBAL VALUE OF GENOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 229
PROTEOMICS LOAC MARKET BY END-USE INDUSTRY 230
TABLE 119 GLOBAL VALUE OF PROTEOMIC LAB-ON-A-CHIP BY END-USER
INDUSTRY, THROUGH 2018 ($ MILLIONS) 230
PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE 232
TABLE 120 GLOBAL VALUE OF PROTEOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2018 232
NGS MARKETS 233
NGS MARKETS BY END-USER INDUSTRY 233
TABLE 121 GLOBAL VALUE OF NGS MARKET BY END-USER INDUSTRY, THROUGH
2018 ($ MILLIONS) 233
NGS MARKET BY SUBSTRATE TYPE 234
TABLE 122 GLOBAL VALUE OF NGS BY SUBSTRATE MATERIAL, THROUGH 2018 ($
MILLIONS) 234
NGS MARKETS BY TEST COMPLEXITY 235
TABLE 123 GLOBAL VALUE OF NGS BY TEST COMPLEXITY, THROUGH 2018 ($
MILLIONS) 235
BIOCHIPS DIAGNOSTICS MARKETS 237
INTRODUCTION 237
DIAGNOSTICS MARKET BY BIOCHIP TYPE 237
TABLE 124 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY BIOCHIP TYPE, THROUGH
2018 ($ MILLIONS) 238
TABLE 125 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 240
DIAGNOSTICS MARKET BY INDICATION 241
TABLE 126 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY INDICATION, THROUGH
2018 ($ MILLIONS) 241
DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL 245
TABLE 127 GLOBAL VALUE OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 246
CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE 246
TABLE 128 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE,
THROUGH 2018 ($ MILLIONS) 247
CANCER DIAGNOSTICS MARKET BY INDICATION 248
TABLE 129 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY INDICATION,
THROUGH 2018 ($ MILLIONS) 248
TABLE 130 2013 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER
APPLICATIONS 249
BIOCHIPS GEOGRAPHIC MARKETS 251
GEOGRAPHY MARKET SUMMARY 251
TABLE 131 GLOBAL VALUE OF BIOCHIPS MARKET BY GEOGRAPHY, THROUGH 2018
($ MILLIONS) 251
MICROARRAY MARKET BY GEOGRAPHY 252
TABLE 132 GLOBAL VALUE OF MICROARRAY MARKET BY GEOGRAPHY, THROUGH
2018 ($ MILLIONS) 253
LOAC MARKET BY GEOGRAPHY 254
TABLE 133 GLOBAL VALUE OF LOAC MARKET BY GEOGRAPHY, THROUGH 2018 ($
MILLIONS) 254
NGS MARKET BY GEOGRAPHY 255
TABLE 134 GLOBAL VALUE OF NGS MARKET BY GEOGRAPHY, THROUGH 2018 ($
MILLIONS) 255

CHAPTER 10 BIOCHIPS PATENTS 258

MICROARRAY PATENTS 258
TABLE 135 DNA MICROARRAY PATENTS BY REGION, 2002-2012 258
TABLE 136 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 259
LOAC PATENTS 259
TABLE 137 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 260
CLINICAL NEXT-GENERATION SEQUENCING PATENTS 260
CLINICAL NGS PATENTS SUMMARY 260
TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 261
CLINICAL NGS PATENTS BY INDICATION 261
TABLE 139 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION,
2002-2012 261

CHAPTER 11 COMPANY PROFILES 264

3QBD 264
20/20 GENE SYSTEMS, INC. 264
ABAXIS, INC. 265
ABBOTT LABORATORIES 266
ABIONIC SA 266
ABTECH SCIENTIFIC, INC. 267
ABACUS DIAGNOSTICA LTD. 267
ACCELERATE DIAGNOSTICS, INC. 268
ACEA BIOSCIENCES, INC. 268
ACHIRA LABS PVT. LTD. 268
ADVANCED LIQUID LOGIC 269
AFFYMETRIX, INC. 269
AGENDIA BV 271
TABLE 140 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE 271
AGENIX LTD. 272
AGILENT TECHNOLOGIES, INC. 272
AKONNI BIOSYSTEMS 273
TABLE 141 AKONNI BIOCHIP GRANTS 274
ALERE TECHNOLOGIES GMBH 275
ALLEGRO DIAGNOSTICS CORP. 276
ALMAC GROUP, LTD. 277
ANAGNOSTICS BIOANALYSIS GMBH 277
ANALYTIK JENA AG 278
AQUAMARIJIN MICRO FILTRATION BV 279
AQUILA DIAGNOSTIC SYSTEMS INC. 279
ARCXIS BIOTECHNOLOGIES, INC. 279
ARRAYIT CORPORATION 280
ASSURERX HEALTH, INC. 281
ATONOMICS A/S 281
AUSHON BIOSYSTEMS, INC. 282
AUTOGENOMICS, INC. 282
AVACTA GROUP PLC 283
AVIANA MOLECULAR TECHNOLOGIES 283
AXELA, INC. 284
AYANDA BIOSYSTEMS SA 284
AYOXXA BIOSYSTEMS GMGH 285
BECKMAN COULTER, INC. 285
BECKMAN COULTER BIOMEDICAL GMBH 286
BECTON, DICKINSON AND CO. 286
BIOCARTIS SA 288
BIOCEPT, INC. 288
BIODOT, INC. 289
BIOFIRE DIAGNOSTICS, INC. 289
BIOFLUIDIX GMBH 290
BIOFORCE NANOSCIENCES, INC. 290
BIOMERIEUX SA 290
BIONANOGENOMICS, INC. 291
BIORAD LABORATORIES, INC. 292
BIOSCALE, INC. 293
BIOSURFIT, SA 293
BIOSYSTEMS INTERNATIONAL 294
BIOTRAY 294
BIOVITESSE, INC. 294
BLUE4GREEN 295
BODITECH MED, INC. 295
BOEHRINGER INGELHEIM MICROPARTS GMBH 295
BOSTON MICROFLUIDICS 296
CAMBRIDGE BIOMAGNETICS LTD. 296
CANCER GENETICS, INC. 296
CAPITALBIO CORPORATION 297
CARIS LIFE SCIENCES 298
CBC COMPREHENSIVE BIOMARKER CENTER GMBH 298
CELLANYX DIAGNOSTICS, INC. 298
CELLASIC 299
CELLECTRICON AB 299
CELLIX, LTD. 300
CELLSCAPE CORPORATION 300
CELLULA, INC. 300
CELLULAR RESEARCH, INC. 301
CEPHEID 301
CLEARBRIDGE BIOMEDICS 302
COMBIMATRIX MOLECULAR DIAGNOSTICS, INC. 303
COURTAGEN LIFE SCIENCES, INC. 303
CREATIVE MICROSYSTEMS CORPORATION 304
CUSTOMARRAY, INC. 304
CYBRDI, INC. 304
CYCLOFLUIDIC LTD. 305
CYNVENIO BIOSYSTEMS, INC. 305
CYTOCENTRICS BIOSCIENCE GMBH 306
CYTOO SA 306
DAKTARI DIAGNOSTICS, INC. 306
DEBIOTECH S.A. 307
DELTADOT LTD. 307
DEOS LABS 307
DIAGENIC ASA 308
DIAGNOSTICS FOR ALL 308
DIAGNOSWISS S.A. 309
DIAXONHIT 310
DIGITAL GENOMICS 310
DNA ELECTRONICS LTD. 311
DNA LINK, INC. 311
DNAMICROARRAY, INC. 312
DOLOMITE MICROFLUIDICS LTD. 312
DR. CHIP BIOTECH, INC. 313
DST DIAGNOSTISCHE SYSTEME and TECHNOLOGIEN GMBH 313
DYCONEX AG 314
EKSIGENT 314
ELIM BIOPHARMACEUTICALS, INC. 314
EPIGEM LTD. 315
EPOCAL, INC. 315
EUROIMMUN AG 315
ELEVFLOW 316
FALCON GENOMICS, INC. 316
FLUIDIGM CORPORATION 317
FLUIMEDIX APS 318
FLUIDWARE TECHNOLOGIES, INC. 318
FLUIMETRICS, INC. 319
FLUXION BIOSCIENCES, INC. 319
FLYION GMBH 319
FULL MOON BIOSYSTEMS, INC. 320
GEN9, INC. 320
GENALYTE 320
GENEFLUIDICS, INC. 321
GENENEWS 321
GENEPOC, INC. 321
GENMARK DIAGNOSTICS, INC. 322
GENOMEDX BIOSCIENCES, INC. 323
GENOMICA SAU 323
GIGAGEN, INC. 324
GNUBIO, INC. 324
GOOD START GENETICS, INC. 325
GRACE BIO LABS 326
GRADIENTECH AB 326
GWC TECHNOLOGIES, INC. 326
GYROS AB 327
HNU-NANOPOINT 327
HOLOGIC, INC. 327
ILLUMINA, INC. 328
IMMUNOVIA AB 330
INNANOVATE, INC. 330
INNOSIEVE DIAGNOSTICS BV 331
INOSTICS GMBH 331
INSTITUTE OF MICROCHEMICAL TECHNOLOGY CO., LTD. 331
INTAVIS BIOANALYTICAL INSTRUMENTS AG 332
INTEGRATED PLASMONICS CORP. 332
INTEL CORPORATION 333
IQUUM, INC. 333
IRIS BIOTECHNOLOGIES, INC. 333
ISU ABXIS CO., LTD. 334
JOHNSON and JOHNSON 335
JPT PEPTIDE TECHNOLOGIES GMBH 335
KINEXUS BIOINFORMATICS CORPORATION 336
KUMETRIX, INC. 337
LAB21 HEALTHCARE LTD. 337
LABORATORY CORPORATION OF AMERICA, INC. 338
LC SCIENCES 338
LEUKODX LTD. 339
LIFE BIOSCIENCES, INC. 339
LIFE TECHNOLOGIES, INC. 340
LINEAGEN, INC. 342
LIONIX BV 342
LUMINEX 343
MAGARRAY, INC. 344
MAXWELL SENSORS INC. 344
MEDIMATE B.V. 345
MERCK KGAA 345
METAMARK GENETICS, INC. 346
MICROFLUIDIX, INC. 346
MICRO2GEN LTD. 346
MICROCHIPS, INC. 347
MICRODISH BV 347
MICRODROP TECHNOLOGIES GMBH 348
MICROFAB TECHNOLOGIES, INC. 348
MICROFLEXIS GMBH 348
MICROFLUIDIC CHIPSHOP GMBH 349
MICROFLUIDIC INNOVATIONS, LLC 349
MICROLIQUID 350
MICROLYTIC 350
MICRONICS, INC. 350
MICRONIT MICROFLUIDICS BV 351
MICROPOINT BIOSCIENCES, INC. 352
MICRUX TECHNOLOGIES SA 352
MINGYUAN MEDICARE DEVELOPMENT COMPANY, LTD. 352
MOBIDIAG OY/LTD. 353
MODE DX, LTD. 353
MOLECULAR CYTOMICS INC. 354
MOLECULAR VISION LTD 354
MYCROARRAY, INC. 355
MYCROLAB DIAGNOSTICS PTY LTD. 355
NANION TECHNOLOGIES GMBH 356
NANO TERRA, INC. 356
NANOBIOSYM 356
NANOBIOSYS 357
NANOCELLECT BIOMEDICAL INC. 357
NANOENTEK, INC. 358
NANOIVD, INC. 358
NANOLABWARE S.A.S.U. 359
NANOMI BV 359
NANOMIX, INC. 359
NANOSPEED DIAGNOSTICS, INC. 360
NANOSPHERE, INC. 360
NANOSTRING TECHNOLOGIES INC. 361
NEC CORPORATION 362
NEOGEN CORPORATION 362
NEOGENOMICS LABORATORIES 363
NETBIO, INC. 363
NEXUS DX, INC. 363
NOVARTIS 364
NUCLEA BIOTECHNOLOGIES, INC. 364
ON-Q-ITY 364
OPKO HEALTH, INC. 365
OPTOTRACK, INC. 366
OSMOTEX AG 366
OSTENDUM RandD BV 366
OXFORD GENE TECHNOLOGY 367
PAMGENE INTERNATIONAL BV 367
PATHGEN DX PTE. LTD. 368
PATHOGENETIX, INC. 368
PATHOGENICA 369
PEPPERPRINT GMBH 370
PEPSCAN PRESTO BV 370
PERKINELMER 370
PHALANX BIOTECH GROUP 372
PHILIPS ELECTRONICS NV 372
PLC DIAGNOSTICS, INC. 373
PLEXERA, LLC 373
POSITIVE ID CORPORATION 374
PROTAGEN AG 374
PROTEIN BIOTECHNOLOGIES, INC. 375
PROTEUS DIGITAL HEALTH, INC. 375
PROTNETEOMIX SAS 375
QIAGEN 376
QIAGEN MARSEILLE 376
Q-LINEA AB 377
QUANTERIX CORPORATION 377
QUANTISCIENTIFICS, LLC 378
QUANTUM DX 378
QUEST DIAGNOSTICS 379
RAINDANCE TECHNOLOGIES, INC. 380
RANDOX LABORATORIES, LTD. 381
RAYBIOTECH, INC. 381
RETROGENIX LTD. 382
RHEONIX 382
RHEOSENSE, INC. 382
RIDGE DIAGNOSTICS, INC. 383
ROCHE HOLDING AG 383
ROSETTA GENOMICS INC. 384
TABLE 142 ROSETTA’S DIAGNOSTICS TESTS 384
SAMSUNG ELECTRONICS CO. LTD. 385
SANDSTONE DIAGNOSTICS, INC. 385
SAVYON DIAGNOSTICS, LTD. 385
SCIENION AG 386
SEEGENE, INC. 387
TABLE 143 SEEGENE BIOCHIPS COLLABORATIONS 387
SENGENICS INTERNATIONAL PTE LTD 388
SENSIMED AG 389
SENSIVIDA MEDICAL TECHNOLOGIES 389
SENSLAB GMBH 390
SENZAIR B.V. 390
SFC FLUIDICS, LLC 390
SHANGHAI BIOCHIP CO., LTD. 391
SHANGHAI HUAGUAN BIOCHIP CO., LTD. 391
SHARP CORPORATION 392
SIALIX, INC. 392
SIGNAL GENETICS, LLC 392
SIGNATURE DIAGNOSTICS AG 393
SILICON BIOSYSTEMS 394
SILOAM BIOSCIENCES, INC. 394
SKYLINE DIAGNOSTICS B.V. 394
SLIPCHIP LLC 395
SOMALOGIC, INC. 395
SONY DADC 396
SOPHION BIOSCIENCE A/S 397
SPARTAN BIOSCIENCES INC. 397
SPHERE FLUIDICS LIMITED 398
SPHERE MEDICAL LTD. 398
SPINCHIP DIAGNOSTICS AS 399
SPINOMIX 399
SQI DIAGNOSTICS, INC. 399
SUPERIOR NANOBIOSYSTEMS 400
SURMODICS, INC. 400
SURNETICS 400
T2 BIOSYSTEMS 401
TEARLAB CORPORATION 401
TECAN GROUP LTD. 402
THERMO FISHER SCIENTIFIC, INC. 402
THINXXS MICROTECHNOLOGY AG 403
TIANJIN BIOCHIP CORPORATION 404
TIRF LABS, INC. 404
TRANSGENOMIC, INC. 404
TRANSLUME, INC. 405
TRIANJA TECHNOLOGIES, INC. 405
TRINEAN NV 406
TRINITY BIOTECH PLC 406
TROVAGENE, INC. 407
US BIOMAX, INC. 407
VERACYTE INC. 408
VEREDUS LABORATORIES PTE, LTD. 408
WAFERGEN BIOSYSTEMS, INC. 409
WASATCH MICROFLUIDICS 409
WAVE 80 BIOSCIENCES 410
WUXI BUOSHENG BIO-ENGINEERING CO., LTD. 410
XAGENIC, INC. 411
XONA MICROFLUIDICS LLC 411
YMC CO., LTD. 411
ZELLKRAFTWERK GMBH 412
ZYOMYX, INC. 412
ZYOXEL LTD. 413



LIST OF TABLES

SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH
2018 ($ MILLIONS) 7
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 11
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 12
TABLE 3 BIOCHIP NOMENCLATURE 13
TABLE 4 SCOPE OF REPORT 14
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2018
($ MILLIONS) 15
TABLE 6 GLOBAL VALUE OF BIOCHIPS BY ANALYSIS FUNCTION, THROUGH 2018 ($
MILLIONS) 16
TABLE 7 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES 17
TABLE 8 COMPARISON OF BIOCHIPS INDUSTRIES 18
TABLE 9 THE NANOSCALE WORLD 21
TABLE 10 MICROARRAY TYPES 22
TABLE 11 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 22
TABLE 12 MICROARRAY GENOME CONTENT 25
TABLE 13 DNA MICROARRAY PLATFORM FEATURES 26
TABLE 14 DNA MICROARRAY APPLICATIONS 27
TABLE 15 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 28
TABLE 16 SNP MEASUREMENT PLATFORMS 31
TABLE 17 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 34
TABLE 18 WORKFLOW FOR A MICRO-RNA EXPERIMENT 36
TABLE 19 BEAD-BASED ARRAYS VERSUS PLANAR MICROARRAYS 37
TABLE 20 PROTEIN MICROARRAY PLATFORMS 40
TABLE 21 PROTEIN MICROARRAYS AS RESEARCH TOOLS 41
TABLE 22 PROTEIN MICROARRAY PRODUCT TYPES 42
TABLE 23 PROTEIN MICROARRAY TECHNICAL CHALLENGES 44
TABLE 24 EMERGING MICROARRAY TECHNOLOGIES 47
TABLE 25 LOAC PRODUCT LIFE CYCLE STAGE 51
TABLE 26 BIOCHIPS SUBSTRATE MATERIALS 52
TABLE 27 LOAC TYPES 53
TABLE 28 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA
SEQUENCING PLATFORMS 58
TABLE 29 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES 58
TABLE 30 LOAC MARKET SEGMENTS 60
TABLE 31 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 61
TABLE 32 LOAC TECHNOLOGY CHALLENGES 62
TABLE 33 BIOCHIP KEY LIFE-SCIENCES MARKET SEGMENTS 65
TABLE 34 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 68
TABLE 35 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 74
TABLE 36 DIAGNOSTICS PARADIGM SHIFT 79
TABLE 37 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 80
TABLE 38 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS 81
TABLE 39 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 83
TABLE 40 COMPARISON OF DNA-BASED MDX PLATFORMS 86
TABLE 41 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS
INTO THE MDX MARKET 87
TABLE 42 ESTIMATED U.S. INCIDENCE FOR SELECTED CANCERS, 2012 92
TABLE 43 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 93
TABLE 44 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT
DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 96
TABLE 45 BREAST CANCER MDX TECHNOLOGY PLATFORMS 97
TABLE 46 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 98
TABLE 47 STATUS OF ADVANCED HPV DIAGNOSTICS 104
TABLE 48 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL
CANCER 107
TABLE 49 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS 108
TABLE 50 CANCER UNKNOWN PRIMARY INDUSTRY 111
TABLE 51 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 113
TABLE 52 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 114
TABLE 53 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS 117
TABLE 54 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS 118
TABLE 55 FIVE-YEAR SURVIVAL RATES FOR NON SMALL CELL LUNG CANCER (%) 119
TABLE 56 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 120
TABLE 57 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 125
TABLE 58 EARLY SCREENING OVARIAN CANCER TESTS 126
TABLE 59 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS 127
TABLE 60 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS 129
TABLE 61 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 132
TABLE 62 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS 135
TABLE 63 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND BY
TECHNOLOGY 136
TABLE 64 IMPORTANCE OF CYP GENES IN DRUG METABOLISM 138
TABLE 65 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS 139
TABLE 66 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS 142
TABLE 67 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 144
TABLE 68 STATUS OF CT/NG ADVANCED DIAGNOSTICS 146
TABLE 69 ALZHEIMER’S DISEASE DIAGNOSTICS APPROACHES 148
TABLE 70 STATUS OF ALZHEIMER’S DISEASE ADVANCED DIAGNOSTICS TESTS 148
TABLE 71 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE 151
TABLE 72 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS 153
TABLE 73 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 155
TABLE 74 HLA TESTING MARKET 157
TABLE 75 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2013 161
TABLE 76 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013 165
TABLE 77 LOC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013 169
TABLE 78 LOAC COMPETITOR LANDSCAPE 178
TABLE 79 LEADING LOAC INSTRUMENT MANUFACTURERS 180
TABLE 80 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS 181
TABLE 81 LOAC DIAGNOSTICS INDUSTRY 182
TABLE 82 ION CHANNEL SCREENING INDUSTRY 183
TABLE 83 DIGITAL PCR INDUSTRY 184
TABLE 84 LOC UNIVERSITY SPIN-OFFS 185
TABLE 85 LEADING LIFE SCIENCE COMPANIES ACQUISITIONS IN LOAC 186
TABLE 86 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL
PHASE 187
TABLE 87 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 188
TABLE 88 LABEL-FREE DETECTION INDUSTRY 189
TABLE 89 NANOARRAY INDUSTRY 191
TABLE 90 KEY PEPTIDE MICROARRAY COMPANIES 192
TABLE 91 KEY ANTIBODY MICROARRAY COMPANIES 193
TABLE 92 MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES 194
TABLE 93 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES 195
TABLE 94 CTC BIOCHIPS INDUSTRY 198
TABLE 95 NORTH AMERICAN TEST COSTS AND PRICES ($) 200
TABLE 96 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 201
TABLE 97 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS 202
TABLE 98 POC CD4 INDUSTRY 203
TABLE 99 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY 204
TABLE 100 CHINA BIOCHIP INDUSTRY 206
TABLE 101 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES 210
TABLE 102 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2018 ($
MILLIONS) 211
TABLE 103 GLOBAL VALUE OF BIOCHIP MARKET BY END-USE INDUSTRY, THROUGH
2018 ($ MILLIONS) 212
TABLE 104 BIOCHIPS SUBSTRATE MATERIALS 213
TABLE 105 GLOBAL VALUE OF BIOCHIP MARKET BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 213
TABLE 106 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2018 ($
MILLIONS) 214
TABLE 107 GLOBAL VALUE OF DNA MICROARRAYS BY ANALYSIS TYPE, THROUGH
2018 ($ MILLIONS) 216
TABLE 108 GLOBAL VALUE OF DNA MICROARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 219
TABLE 109 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY 220
TABLE 110 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2018
($ MILLIONS) 221
TABLE 111 GLOBAL VALUE OF PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 223
TABLE 112 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 223
TABLE 113 GLOBAL VALUE OF PROTEOMIC ARRAYS BY ARRAY TYPE, THROUGH 2018
($ MILLIONS) 224
TABLE 114 GLOBAL VALUE OF EMERGING ARRAYS, BY ARRAY TYPE, THROUGH 2018
($ MILLIONS) 225
TABLE 115 GLOBAL VALUE OF EMERGING ARRAYS BY END USE, THROUGH 2018 ($
MILLIONS) 226
TABLE 116 GLOBAL VALUE OF EMERGING ARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 227
TABLE 117 GLOBAL VALUE OF GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY,
THROUGH 2018 ($ MILLIONS) 228
TABLE 118 GLOBAL VALUE OF GENOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2018 ($ MILLIONS) 229
TABLE 119 GLOBAL VALUE OF PROTEOMIC LAB-ON-A-CHIP BY END-USER INDUSTRY,
THROUGH 2018 ($ MILLIONS) 230
TABLE 120 GLOBAL VALUE OF PROTEOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2018 232
TABLE 121 GLOBAL VALUE OF NGS MARKET BY END-USER INDUSTRY, THROUGH
2018 ($ MILLIONS) 233
TABLE 122 GLOBAL VALUE OF NGS BY SUBSTRATE MATERIAL, THROUGH 2018 ($
MILLIONS) 234
TABLE 123 GLOBAL VALUE OF NGS BY TEST COMPLEXITY, THROUGH 2018 ($
MILLIONS) 235
TABLE 12

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report discusses market growth, size and opportunities with respect to applications, geographic region and technologies. Forecast trends and revenue are given through 2019. Major players, ...

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report provides an overview of the current state of the microRNA (miRNA) market, focusing mainly on continuing research endeavors, newly emerging sophisticated tools, reagents, techniques, ...

Global Bioinformatics Industry

July 2014 $ 4 950

1 Companies

Company Profiles

ForeverGreen IP L.L.C.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.